c4c Multi-Stakeholder Meeting on Paediatric Inflammatory Bowel Disease

First c4c Multi-Stakeholder Meeting on Paediatric Inflammatory Bowel Disease (IBD) More than 100 stakeholders from academia, industry, regulators and patients/patient associations attended our first Multi-Stakeholder Meeting (MSM) on April 14 and 15, 2021. Background MSMs are designed to facilitate discussion and interaction among relevant stakeholders on the development of medicines in the best interest of children…

Strategic feasibility expert advice groups

Strategic feasibility expert advice groups One of the key activities of c4c is to set up an advice process to facilitate expert advice, (Strategic Feasibility Advice) to c4c industry and academic beneficiaries on any aspect of a paediatric drug research and/or development project (e.g., study design including methodology, assistance with regulatory responses). More than 300…

Patient and Public Involvement (PPI)

Patient and Public Involvement (PPI) The voice of the patient in clinical research and development is increasingly being included, from the setting of research priorities through to the dissemination of results. This marks a shift in what has historically and culturally been, until relatively recently, research “on” rather than “with” patients.  Previously, researchers defined their…

What are the c4c National Hubs (NHs)?

What are the c4c National Hubs (NHs)? Paediatric research has multiple challenges and these challenges become obstacles when the research infrastructure is not well-prepared to overcome them. There is a huge need to work in a coordinated way, between multiple partners and countries, to improve the design and implementation of paediatric trials. c4c has sought…

Meet the project leadership team!

Introducing the c4c project leadership team: Carlo Giaquinto (Penta – project coordinator) Mark Turner (University of Liverpool – co-coordinator) Katharine Cheng (Janssen – project lead) Heidrun Hildebrand (Bayer – co-project lead). We lead and supervise the overall progress of c4c, with the support of the project management office, and by working closely with Work Package…

What are patients’ needs and how to improve the development of medicines?

What are patients’ needs and how to improve the development of medicines?  First c4c Multi-Stakeholder Meeting on paediatric Inflammatory Bowel Disease (IBD).  c4c held its first International Multi-Stakeholder Meeting (MSM) on paediatric Inflammatory Bowel Disease (IBD) virtually on 14-15 April 2021. Over 100 individuals participated, representing patients and advocates, clinicians, academics, pharmaceutical companies and regulators.…

c4c – the WHY and the HOW

We are working to ensure children have the same rights as adults to access high quality, evidence-based medicines and health care services. We are fully committed to increasing high quality paediatric research.